Nurse-led Physician-supported Care for Patients With Chronic Kidney Disease and Multimorbidity

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorAlexandra Hospital

About this trial

Chronic kidney disease (CKD) is a prevalent chronic disease and is often intertwined with the management of cardiovascular disease and the optimization of metabolic risk factors. In light of steeply rising rates of end-stage kidney disease (ESKD) and increased healthcare resource utilization by CKD patients, the investigators propose that the role of nurses could be expanded to support the care of CKD patients in the community.

A total of 220 patients will be randomized (1:1) to the intervention or control groups (usual care). The intervention entails enrolment into a nurse-led, physician-supported programme (INTEGREAT-CKD), comprising outpatient consultations and community-based ambulatory monitoring and counselling primarily driven by CKD-trained advanced practice nurses (APNs) and healthcare professionals conducted over 6 months. Patient-reported outcomes like health-related quality of life (HRQOL), as measured by EQ-5D and KDQOL, CKD self-management score and CKD health literacy will be assessed at baseline and after 6 months. The primary outcome is CKD self-management. Other secondary outcomes to be assessed and tracked including achievement of clinical targets relevant to slowing down CKD progression, attainment of CKD best practice guidelines as specified in the KDIGO CKD Evaluation and Management guidelines 2020.

Eligibility criteria

Qualifiers

Adults aged 21 years and above AND diagnosed with

CKD Stages 3B and above (defined as estimated GFR less than or equal to 44 mL/min/1.73m2 with evidence of kidney damage) AND diagnosed with

one or more of the following sub-optimally managed parameters pertaining to blood pressure control OR, glycemic control OR fluid status management.

Disqualifiers

Pregnancy

End stage kidney disease

Enrolment in any structured outpatient-based or community-based CKD program for at least six months prior to or during the period of enrolment in the study.

Dementia and/or cognitive impairment

Trial design

Treatments tested in this trial

  • INTEGREAT-CKD Intervention

Treatment groups

220 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Alexandra Hospital

Lead sponsor

National University Hospital, Singapore

Collaborator